SCHEMBL4576532

SCHEMBL4576532

CC(=O)Oc1c(C=Cc2ccccc2)cc(OC(=O)CCl)c(C(C)C)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
RAB9A P51151 4/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 3/20 0.40
HTT P42858 3/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 3/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 1/20 0.38
AHR P35869 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
TP53 P04637 1/20 0.36
NFKB1 P19838 1/20 0.36
MAPK1 P28482 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918613 0.85 AHR (0.43) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL4576529 0.80 AHR (0.51) ALDH1A1MAPTHTTLMNAAHR
SCHEMBL918612 0.80 AHR (0.51) ALDH1A1MAPTHTTLMNAAHR
SCHEMBL5182137 0.77 KMT2A (0.45) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL5182132 0.74 TUBB4A (0.49) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL918690 0.74 AHR (0.55) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL918688 0.74 AHR (0.55) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL3452158 0.72 TUBB4A (0.46) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL28030057 0.72 TUBB4A (0.46) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL3837232 0.72 KMT2A (0.47) KMT2AMEN1RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255245-A1 Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues WELICHEM BIOTECH INC. (CA) 2008-10-16 US disclosed
US-7321050-B2 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH INC. (CA) 2008-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255245-A1 Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues NFKBIA, IKBKB, IKBKE KMT2A 2517/4885MEN1 4474/4885RAB9A 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.